Focus on Japan | Biocom Debuts at CPHI Japan, Exploring New Heights in Pharmaceutical Innovation And Quality

Recently, the Biocom team traveled to Tokyo, Japan, to attend the CPHI World Pharmaceutical Raw Materials Exhibition (Japan) held at the Tokyo Big Sight from April 21 to 23, 2026. As one of Asia’s premier industry events renowned for high quality and innovation, the Biocom team gathered with pharmaceutical elites from around the world to exchange cutting-edge technologies and explore collaboration opportunities, injecting new vitality into expanding the high-end East Asian market and advancing pharmaceutical technology cooperation under the framework of the Belt and Road Initiative.

During the exhibition, the Biocom team, with a rigorous and professional approach, received numerous seasoned industry clients from Japan, South Korea, Southeast Asia, and beyond. In response to the Japanese market’s extremely high demands for product quality, process details, and regulatory compliance, the team showcased a range of core APIs and intermediates featuring mature processes and robust quality systems. Through in-depth technical Q&A sessions and market prospect analyses, both sides conducted multiple rounds of productive discussions on complex registration pathways and stringent supply chain audit standards. As a result, preliminary cooperation contacts were established with several leading Japanese companies in niche segments, laying a solid foundation for further expansion into this key market.

Guided by its core values of “Integrity, Innovation, Responsibility, and Sharing,” Biocom has built a full-industry-chain platform covering innovative R&D, GMP manufacturing bases (Loncom Pharmaceutical), and international registration and MAH holding. We always adhere to ICH guidelines and strive to meet the world’s most demanding market standards, including those of Japan.

This trip to Tokyo was not only a successful market expansion but also a deep benchmarking and learning experience. Biocom sincerely thanks all clients and partners who visited and exchanged ideas with us during the exhibition, placing their trust in us! We look forward to joining hands with you, with unremitting innovation and outstanding “Chinese quality,” to jointly tackle the challenges of the global pharmaceutical industry, contribute greater wisdom and strength to human health, and draw a new blueprint for the synergistic development of the East Asian pharmaceutical industry.